Kindred Biosciences (NASDAQ: KIN) and Aduro BioTech (NASDAQ:ADRO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.
Earnings and Valuation
This table compares Kindred Biosciences and Aduro BioTech’s gross revenue, earnings per share and valuation.
||Earnings Per Share
Kindred Biosciences has higher earnings, but lower revenue than Aduro BioTech. Kindred Biosciences is trading at a lower price-to-earnings ratio than Aduro BioTech, indicating that it is currently the more affordable of the two stocks.
This table compares Kindred Biosciences and Aduro BioTech’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a breakdown of current ratings for Kindred Biosciences and Aduro BioTech, as reported by MarketBeat.com.
||Strong Buy Ratings
Kindred Biosciences currently has a consensus price target of $9.90, indicating a potential upside of 20.73%. Aduro BioTech has a consensus price target of $18.50, indicating a potential upside of 203.28%. Given Aduro BioTech’s stronger consensus rating and higher probable upside, analysts clearly believe Aduro BioTech is more favorable than Kindred Biosciences.
Institutional & Insider Ownership
66.7% of Kindred Biosciences shares are owned by institutional investors. Comparatively, 45.1% of Aduro BioTech shares are owned by institutional investors. 19.1% of Kindred Biosciences shares are owned by insiders. Comparatively, 6.6% of Aduro BioTech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
About Kindred Biosciences
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company’s other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
About Aduro BioTech
Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.
Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.